Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of non-small cell lung cancer

          -  Clinical American Joint Committee on Cancer (AJCC) (AJCC, 7th ed.) II, IIIA or IIIB
             (with non-operable disease; non-operable disease will be determined by a
             multi-disciplinary treatment team within 60 days prior to registration; note: for
             patients who are clearly nonresectable, the case can be determined by the treating
             radiation oncologist and/or a medical oncologist or pulmonologist

               -  Patients who present with N2 or N3 disease and an undetectable NSCLC primary
                  tumor are eligible

               -  Patients who refuse surgery are eligible

               -  Patients who develop local recurrence after surgery and rendered candidate for
                  definitive concurrent chemoradiation are also eligible

               -  Patients who have received systemic treatment (up to 4 cycles of induction
                  chemotherapy, or up to 6 months of targeted therapy) are eligible

          -  Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               -  History/physical examination within 30 days prior to registration including
                  resting heart rate;

               -  Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography
                  (CT) scan for staging within 60 days prior to registration

               -  Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or
                  CT scan of the brain with contrast within 60 days prior to registration;

               -  Forced expiratory volume in one second (FEV1) >= 0.8 liter or >= 35% predicted
                  with or without bronchodilator within 90 days prior to registration;

                    -  Patients who meet the criterion above without oxygen (O2), but who need
                       acute (started within 10 days prior to registration) supplemental oxygen due
                       to tumor-caused obstruction/hypoxia are eligible, provided the amount of the
                       O2 needed has been stable

          -  Zubrod performance status 0-1 within 30 days prior to registration

          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 obtained within 30 days prior to
             registration

          -  Platelets >= 100,000 cells/mm^3 obtained within 30 days prior to registration

          -  Hemoglobin >= 9.0 g/dl (note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] >= 9.0 g/dl is acceptable), obtained within 30 days prior to
             registration

          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate
             transaminase (SGPT) within 30 days prior to registration

               -  It is highly recommended but not required that SGOT or SGPT be =< 1.5 upper limit
                  of normal

          -  Total bilirubin =< 1.5 within 30 days prior to registration

               -  It is highly recommended but not required that total bilirubin be =< 1.5 upper
                  limit of normal

          -  Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min within 30
             days prior to registration estimated by the Cockcroft-Gault formula

          -  Peripheral neuropathy =< grade 1 at the time of registration

          -  Patients with non-malignant pleural effusion are eligible

               -  If a pleural effusion is present, the following criteria must be met to exclude
                  malignant involvement:

                    -  When pleural fluid is visible on both the CT scan and on a chest x-ray, a
                       pleuracentesis is required to confirm that the pleural fluid is
                       cytologically negative

                    -  Exudative pleural effusions are excluded, regardless of cytology

                    -  Effusions that are minimal (i.e, not visible on chest x-ray) that are too
                       small to safely tap are eligible

          -  Patients must have measurable or evaluable disease

          -  Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to registration

          -  Women of childbearing potential and male participants must practice adequate
             contraception

          -  Patient must provide study-specific informed consent prior to study entry

        Exclusion Criteria:

          -  Prior invasive malignancy unless disease free for a minimum of 3 years; however, skin
             cancer and in situ carcinomas of the breast, oral cavity, cervix, and other organs and
             are permissible

          -  Patients with prior history of either small cell lung cancer or NSCLC regardless of
             the treatment received, other than patients who have recurrent disease following
             resection

          -  Prior systemic chemotherapy for the study cancer, if more than 4 cycles of induction
             chemotherapy or more than 6 months of targeted therapy; note that prior chemotherapy
             for a different cancer is allowable

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months;

               -  Transmural myocardial infarction within the last 6 months;

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  other than the diagnosed lung cancer requiring hospitalization or precluding
                  study therapy within 30 days before registration;

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
                  Control and Prevention (CDC) definition; note, however, that human
                  immunodeficiency virus (HIV) testing is not required for entry into this protocol

          -  Unintentional weight loss > 10% within 30 days prior to registration

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception